(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
My Pioneering Excursion: Building a Startup - 2FACT FOCUS: Trump sows confusion on number of childhood vaccinations
- 3Find the Marvels of the World with These Travels
- 4Bayer reports positive results for blood thinner after 2023 setback
- 5Director of Swiss hospital describes the rush to treat the injured from Alpine resort bar fire
- Japan deploys the military to counter a surge in bear attacks
- WHO suspends medical evacuations from Gaza following death of contractor in 'security incident'
- Vote In favor of Your #1 Method for diminishing Pressure
- Figure out How to Consolidate Cutting edge innovations in Senior's SUVs
- Dozens killed as Angola flood death toll rises
- Extraordinary Guinness World Records That Will Astound You
- Figure out how to Detect the Best Rooftop Substitution Choices
- How did Hugh Jackman nail his latest role? Sequins, tighty-whities and embracing 'zero embarrassment.'
- 6 Popular Men's Aromas On the planet
